BIO Protocol is a pioneering decentralized science (DeSci) platform designed to revolutionize biotechnology funding and commercialization by enabling global communities of patients, scientists, and professionals to collectively fund, build, and own tokenized biotech projects and intellectual property (IP).

Built on the foundations of predecessors like Molecule and VitaDAO, created by the same team, BIO introduces a financial layer for on-chain science, fostering bioDAOs (community-owned research networks) and creating liquid markets for scientific IP. Key features include curation via BIO token staking, rewards for milestones, and IP Tokens for fractional governance.

The protocol operates within the burgeoning DeSci niche of the broader biotechnology industry. This niche was valued at approximately $1.77T in 2025 and is projected to reach $5.71T by 2034, growing at a CAGR of 13.9%.

BIO's native token ($BIO) has a total supply of 3.32B, with utilities centered on governance, curation, and access to ecosystem perks. Backed by prominent investors like Binance Labs in its genesis round and facilitation of $33M+ in global research funding, BIO is positioned for significant upside in a market driven by AI integration, gene therapies, and personalized medicine.

Risks include regulatory hurdles and competition from established DeSci players, but opportunities in expanding bioDAOs and AI agents suggest strong growth potential. This report evaluates BIO as a high-conviction investment in the DeSci space, with a bullish outlook amid rising chronic disease prevalence and biotech innovation.

Today’s edition of Token Metrics Research | Daily Newsletter is brought to you by Crypto 101.

When you’re teeing off, you square up your shot for the best drive — the same goes for your financial future.

Our $3 report includes our #1 Coin for the market right now, including a step-by-step guide on how to trade it.

Learn to manage risks, make smarter plays, and aim for better outcomes.

Access The Report Now

Now, let’s get back to the deep dive.

BIO Protocol envisions an on-chain scientific economy where decentralized communities (bioDAOs) accelerate biotechnology innovation. By tokenizing biotech projects and IP, it aims to democratize access to funding, governance, and ownership, enabling anyone, scientists, patients, or crypto users, to participate in developing life-saving therapies.

The long-term goal is to bring hundreds of new research communities and biotech assets on-chain by 2025, reshaping biotech from a centralized, slow-moving industry into a collaborative, liquid ecosystem.

Inefficiencies, including high barriers to entry for early-stage research, siloed capital flows, slow commercialization, and limited community involvement, plague traditional biotechnology funding.

Patients and scientists often lack direct stakes in outcomes, while IP remains illiquid and controlled by a few entities. This results in delayed breakthroughs for chronic diseases, high costs (e.g., R&D expenses exceeding $2B per drug), and underfunding for niche areas like longevity or rare diseases. Regulatory bottlenecks and centralized gatekeepers further exacerbate talent and capital mismatches.

BIO Protocol addresses these through a permissionless DeSci framework: communities form bioDAOs to pool resources (capital, data, labor) for R&D, with BIO token holders curating and funding promising projects via a Launchpad.

Tokenized IP (IP-Tokens) allows fractional ownership and governance, while rewards incentivize milestones like clinical trials or product launches. Built on Ethereum with AI agents for scientific tasks, it creates deep, liquid markets for biotech IP, reducing costs, speeding commercialization, and distributing value equitably.

BIO Protocol falls within the Decentralized Science (DeSci) sub-industry, a niche at the intersection of blockchain and biotechnology focused on open, community-driven research funding and IP management.

DeSci leverages web3 tools to decentralize scientific processes, addressing inefficiencies in traditional biotech. While specific DeSci market size data is nascent, it is part of the broader global biotechnology industry.

The global biotechnology market was valued at USD 1.77T in 2025 and is projected to reach USD 5.71T by 2034, growing at a CAGR of 13.9%. This growth is driven by rising chronic disease prevalence (e.g., cancer, diabetes), advancements in gene therapies (CRISPR, mRNA), AI/ML integration in drug discovery, and demand for personalized medicine.

Key reports from Grand View Research and Precedence Research highlight factors like government initiatives (e.g., Healthy China 2030), agricultural biotech for sustainable crops, and industrial applications in bio-manufacturing. North America dominates with a 41.4% share due to R&D investments, while Asia-Pacific grows fastest at over 14.8% CAGR, fueled by healthcare infrastructure and partnerships.

DeSci is competitive, with projects focusing on tokenized funding and IP. Below is a table of the top five competitors to BIO Protocol, based on market cap, focus, and activity. 

The native token is $BIO (ERC-20 on Ethereum), with a total supply of 3.32 billion (dynamic, adjustable via governance) and a circulating supply of ~1.87 billion as of mid-2025.

BIO's team comprises DeSci pioneers with deep biotech and web3 expertise:

BIO has achieved notable milestones since its inception:

BIO Protocol stands out as a leader in DeSci, bridging biotech's trillion-dollar potential with web3's liquidity and community power. With a proven team, strong traction (e.g., $200M+ bioDAO caps), and utilities driving token demand, it is well-positioned for the biotech market's 13.9% CAGR growth to USD 5.71T by 2034.

Bull case: AI agents and bioDAO expansion catalyze a "scientific singularity," yielding 5-10x returns. Bear case: Regulatory risks or market downturns cap upside. Overall, BIO represents a compelling opportunity in on-chain science, recommend monitoring for further launches and integrations. (Not financial advice; do your research.)

The AI economy is booming, and smart entrepreneurs are already profiting. Subscribe to Mindstream and get instant access to 200+ proven strategies to monetize AI tools like ChatGPT, Midjourney, and more. From content creation to automation services, discover actionable ways to build your AI-powered income. No coding required, just practical strategies that work.

Subscribe to Get Your Free Guide